Category Archives: Articles

 

Medicortex Crowdfunding Campaign for Brain Injury Detection Kit

Medicortex has launched a crowdfunding campaign in order to generate support for developing a diagnostic kit for brain injury detection. The target is 200,000 Euro with a maximum of 560,000 Euro offering equity of between 4.76 and 12.28 percent. The price per share is 4 Euro with a minimum investment...
Read more

BioLineRX Acquires Agalimmune

BioLineRx has acquired Agalimmune Ltd., a private UK-based company with an innovative, anti-cancer immunotherapy platform. Acquisition consideration consisted of a $6 million upfront payment, of which $3 million is in cash and the remainder in BioLineRx shares. Additional future payments may be made based on development and commercial milestones. Agalimmune’s...
Read more

FDA Approval for Cervical Cancer Device

The U.S. Food and Drug Administration approved Mobile ODT’s EVA (Enhanced Visual Assessment) System for marketing and sale in the United States. The tragedy of cervical cancer – strongly addressed in major urban areas – still plagues much of America, where it is increasingly difficult for a woman to get...
Read more

New Compugen Immune Checkpoint

Compugen Ltd. (NASDAQ: CGEN) announced development of CGEN-15137, its cancer immunotherapy program for TIGIT. TIGIT is an immune checkpoint in the B7/CD28 family which has recently gained broad industry interest in the field of immuno-oncology. At the recent Annual Meeting of the Society for Immunotherapy of Cancer, the company disclosed...
Read more

BioSight Success in Leukemia Trial

Cancer treatment company BioSight, which recently received a $13 million investment from Mori Arkin and US investment fund Primera Capital, reports positive interim results of an initial efficacy trial for its Leukemia treatment product. The company’s product, Astarabine, had been tested on 15 Acute Myeloid Leukemia (AML) and Acute Lymphoblastic...
Read more

Israeli High-Tech Raises $1.19 Billion

Israeli high-tech companies raised a total of $1.19 billion in the third quarter of 2016, the second highest quarterly amount in 10 years. The amount was significantly affected by the exceptional Ormat PIPE deal of $204 million, which captured 17 percent of total capital raised. Excluding the Ormat transaction, the...
Read more

MDDMI Call for Medical Device Papers

On behalf of the MDDMI 2017 steering committee and the conference chairman, Prof. Rafi Beyar, Director of the Rambam Health Care Campus, we are pleased to invite you to take part at the Israel’s premier event for medical device development. The steering Committee encourages the submission of original Papers for...
Read more

Vaxil Bio Pre-Clinical Cancer Results

VAXIL BIO LTD. (TSX VENTURE: VXL) has reported  preliminary pre-clinical results demonstrating anti-cancer activity of Immucin™ in combination with checkpoint inhibitors. Furthermore, Vaxil’s scientists have made significant progress for Orphan Designated product Immucin™ in demonstrating its ability to act as a neo-antigen, with potential to strongly stimulate the immune system. Vaxil has launched...
Read more

Gour Medical Lists on Paris Stock Market

GOUR Medical, an animal health specialist , has listed on Marché Libre Euronext Paris (ISIN code: CH0342399851; Ticker: MLGML), the French securities market. GOUR Medical is a pharmaceutical company dedicated to the development and marketing of veterinary drugs for mature pets. Having first identified and acquired a number of drug...
Read more

BIOMED 2017 in Tel Aviv May 23-25

The 16th BIOMED 2017 Conference and Exhibition will be held May 23-25, 2017 in Tel-Aviv, Israel. As the leading event of Israel’s life sciences industry, Biomed has positioned itself throughout the years as the main annual meeting place for players of Israel’s healthcare industry with their colleagues from around the globe. It presents...
Read more

Alma Crowdfunds for Crohn’s Therapy

Alma is preparing a therapy for testing in patients with Crohn’s Disease.The company plans to conduct the early stage clinical testing. Then, Alma will license the therapy to a larger company and collect royalties from drug sales. </p> Crowdfunding has emerged as a solution and a major opportunity to find...
Read more

BioLineRx Phase 2a for Pancreatic Cancer

BioLineRx Ltd. (NASDAQ/TASE:BLRX) today announced the initiation of a Phase 2a trial investigating BL-8040 in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with metastatic pancreatic cancer. The Phase 2a study, named the COMBAT study, is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy of...
Read more

Avraham Raises $4M for MCI Trial

Avraham Pharmaceuticals Ltd.  has closed an investment round of approximately $4.0 million. Investors in the round include Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, Pontifax, Clal Biotechnology Industries, Integra Holdings, Yissum’s biotech holdings company, the Technion Research and Development Foundation Ltd. (TRDF)...
Read more

BioBlast Study for OPMD

BioBlast Pharma Ltd. (Nasdaq:ORPN), a clinical-stage, orphan disease-focused biotechnology company, announced positive results from its HOPEMD Phase 2 six-month open-label clinical study in patients with oculopharyngeal muscular dystrophy (OPMD), a rare progressive muscle-wasting disease characterized by swallowing difficulties (dysphagia), leading to the risk of aspiration of food into the lungs,...
Read more

Breast Milk Mimic Improves Brain Function

Enzymotec announced that InCogTM, an innovative lipid composition that is intended to mimic certain characteristics of human breast milk contributing to cognitive development, demonstrated enhanced brain development and improved survival in a preclinical study. The study evaluated the effects of InCogTM in a term and preterm piglet model relevant for...
Read more

Can-Fite Phase III Arthritis

Can-Fite has submitted to the European Medicines Agency (EMA) a protocol design for its Phase III trial and Registration Plan for the Company’s lead compound CF101 in the treatment of rheumatoid arthritis following a pre-submission meeting with the EMA. The global trial is expected to commence in either the second...
Read more

Intensix Teams With Mayo Clinic

Israeli big data and intensive care analytics startup Intensix has signed an agreement with Mayo Clinic in the US to commence a study of early predictions of life-threatening complications in a critical care setting. The study will focus on the feasibility of using the Intensix platform to predict patient deterioration...
Read more

CanFite Alternative to Viagra

An Israeli pharmaceutical firm could be the next big producer of erectile dysfunction treatments. Petah Tikvah-based Can-Fite announced Tuesday that the US Patent and Trademark Office (one of the last stages before the actual granting of a patent) issued a Notice of Allowance for the company’s “A3 Adenosine Receptor Allosteric...
Read more

Telemedicine kit for Home Diagnosis

Your preschooler wakes up with an earache and fever. You tell your boss you’ll be late to work, wangle a pediatrician appointment, bundle up the sick kid, sit in a waiting room full of other sick kids, spend five minutes with the doctor, and leave with a prescription and/or orders...
Read more

TrendLines Deal With Japanese MNC

The Trendlines Group has entered into a definitive collaboration framework agreement with a major multinational medical corporation headquartered in Japan. This research partnership will see the firms mutually identify specific clinical opportunities. As part of the terms of the agreement, Trendlines Labs will develop innovative medical device products for manufacturing...
Read more